A Comparison of Sodium-Glucose Co-Transporter 2 Inhibitor Kidney Outcome Trial Participants with a Real-World Chronic Kidney Disease Primary Care Population.
Anna K ForbesWilliam HintonMichael D FeherWilliam ElsonJosé M Ordóñez-MenaMark JoyXuejuan FanDebasish BanerjeeNicholas I ColeNeil MunroMartin WhyteRebecca J SucklingPauline A SwiftSimon de LusignanPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024)
SGLT2 inhibitor kidney outcome trials represent a sub-group of people with CKD at high risk of adverse kidney events. Out study highlights the importance of complementing trials with real-world studies, exploring the effectiveness of SGLT2 inhibitors in the broader population of people with CKD.